Pages that link to "Q51075545"

The following pages link to Stefan Pusch (Q51075545):

Displaying 42 items.

• Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody (Q28239475) (← links)
• Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases (Q28250795) (← links)
• The Arabidopsis thaliana F-box protein FBL17 is essential for progression through the second mitosis during pollen development (Q33416768) (← links)
• A general G1/S-phase cell-cycle control module in the flowering plant Arabidopsis thaliana (Q34373868) (← links)
• mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy (Q34394233) (← links)
• Proximity ligation assay evaluates IDH1R132H presentation in gliomas (Q35056736) (← links)
• Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. (Q37485784) (← links)
• Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry (Q38410050) (← links)
• Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. (Q38755638) (← links)
• Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway (Q38964993) (← links)
• Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. (Q39000847) (← links)
• Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. (Q40319899) (← links)
• Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma (Q40696725) (← links)
• Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. (Q41114465) (← links)
• D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma (Q41791057) (← links)
• Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations (Q44902948) (← links)
• IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity (Q45048187) (← links)
• CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas (Q45182713) (← links)
• Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. (Q47207803) (← links)
• Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. (Q47394326) (← links)
• T-loop phosphorylation of Arabidopsis CDKA;1 is required for its function and can be partially substituted by an aspartate residue (Q48080797) (← links)
• Analysis of the subcellular localization, function, and proteolytic control of the Arabidopsis cyclin-dependent kinase inhibitor ICK1/KRP1. (Q48086814) (← links)
• A vaccine targeting mutant IDH1 induces antitumour immunity (Q48649314) (← links)
• OS2.2 Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas. (Q50334181) (← links)
• Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein (Q51075492) (← links)
• Control of cell proliferation, organ growth, and DNA damage response operate independently of dephosphorylation of the Arabidopsis Cdk1 homolog CDKA;1. (Q51772392) (← links)
• Brain tumour cells interconnect to a functional and resistant network. (Q52147171) (← links)
• NDRG1 prognosticates the natural course of disease in WHO grade II glioma. (Q53074453) (← links)
• Identification of kinase substrates by bimolecular complementation assays. (Q53204735) (← links)
• Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. (Q54414665) (← links)
• OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas. (Q54479978) (← links)
• Bimolecular-fluorescence complementation assay to monitor kinase-substrate interactions in vivo. (Q54568154) (← links)
• Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. (Q55312873) (← links)
• Glioma IDH1 mutation patterns off the beaten track. (Q55463823) (← links)
• Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective (Q57787518) (← links)
• Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma (Q59134257) (← links)
• CIC protein instability contributes to tumorigenesis in glioblastoma (Q61797528) (← links)
• Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p (Q64082699) (← links)
• Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (Q89486322) (← links)
• Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation (Q90916635) (← links)
• Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E (Q92481479) (← links)
• A cell-based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF-driven pediatric low-grade glioma cells (Q95831151) (← links)